Global lipoprotein (a) testing trends from 2015 to 2023
Authors' conclusion
Global Lp(a) testing rates remain low overall and in high-risk subgroups
Study context
- Population
- Adults (≥18 years), global network, 2015–2023175,853 tested
- Participants
- 141 million adults
- Outcome
- Annual trends in Lp(a) testing overall and in high-risk subgroups
- Follow-up
- January 2015 to December 2023
Methodological detailsTriNetX Global Collaborative Network, 144 healthcare organizations
- TriNetX Global Collaborative Network
- 144 healthcare organizations
Main finding
As reported in the abstract
Overall Lp(a) testing rate · 2015 to 2023
- Overall Lp(a) testing, 2015
- 0.009%
- Overall Lp(a) testing, 2023
- 0.032%
- Coronary artery disease (CAD), 2015–2023
- 0.24%-0.85%
- Peripheral artery disease (PAD), 2015–2023
- 0.20%-0.42%
- Ischemic stroke, 2015–2023
- 0.61%-0.71%
- Heart failure (HF), 2015–2023
- 0.19%-0.51%
- Family history of CAD, 2015–2023
- 0.24%-1.29%
- Carotid artery stenosis, 2015–2023
- 0.37%-0.90%
- AS, 2015–2023
- 0.18%-0.56%
Observational data: associations, not effects.
Further findings
Characteristics of tested patients
- Mean age, years
- 59.0 ± 16.9
- Women
- 50%
- White adults
- 63%
Original publication
Global lipoprotein (a) testing trends from 2015 to 2023. Am Heart J. Published 21 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →